Back to top
more

Idera Pharmaceuticals, Inc. (IDRA)

(Delayed Data from NSDQ)

$3.57 USD

3.57
1,700,174

+0.51 (16.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $3.56 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Aceragen, Inc. [IDRA]

Reports for Purchase

Showing records 1 - 20 ( 169 total )

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

12/20/2021

Company Report

Pages: 6

Termination of Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for IDRA

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

08/13/2021

Daily Note

Pages: 5

Dropping Coverage Due to Realignment of Analyst Resources

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

03/19/2021

Company Report

Pages: 8

ILLUMINATE-301 Fail Not Very Enlightening; Downgrading to NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

03/19/2021

Daily Note

Pages: 14

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

03/19/2021

Company Report

Pages: 6

Negative Readout From Tilsotolimod Phase 3 Study; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 25.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

03/04/2021

Company Report

Pages: 6

Q4 Financials; Phase 3 Tilsotolimod Data Imminent

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

03/04/2021

Daily Note

Pages: 10

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

03/02/2021

Company Report

Pages: 7

All Eyes on Phase 3 Results Expected in March; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 25.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

03/01/2021

Industry Report

Pages: 16

Monthly Check-Up: March 2021

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

10/30/2020

Company Report

Pages: 7

ILLUMINATE-301 Remains on Track to Report in 1Q21; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

10/30/2020

Company Report

Pages: 5

Q3 Financials; ILLUMINATE-301 Remains on Track for 1Q:21 Readout

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 10.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

08/06/2020

Company Report

Pages: 7

All Eyes on Pivotal Phase 3 Results Expected in 1Q21; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

08/05/2020

Company Report

Pages: 5

Q2 Financials; Ph 3 Readout Remains On Track for Q1:21

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 10.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

06/03/2020

Daily Note

Pages: 3

Encouraging Initial Results From ILLUMINATE-206 Study; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

06/02/2020

Daily Note

Pages: 4

Quick Look at ILLUMINATE-206 in MSS-CRC; Additional Cohort Planned

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 10.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

05/06/2020

Daily Note

Pages: 13

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

05/05/2020

Company Report

Pages: 6

Q1 Financials; Cash Runway Tight But Sufficient to Reach Critical Readouts

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

05/01/2020

Company Report

Pages: 6

Cash Runway Extended Until 2Q21; Eyes on Phase 3 Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Aceragen, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

04/29/2020

Industry Report

Pages: 19

Takeaways from First AACR Virtual Meeting

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party
// eof